Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
Research Appreciation Day 2023
Wednesday 5th July 2023 saw the launch of the first Research Appreciation Day, a new annual awareness day to celebrate the hard work of health researchers from across disciplines.
From smaller grants for pilot studies through to larger grants for pre-clinical and clinical trials, we fund the most promising neuroblastoma research with the greatest potential for children with this rare and aggressive cancer.
Rainbow hoodie to give children with cancer a brighter future
As part of its first ever charity collaboration, Ripon-based clothing brand Rosebuds and Pearls will donate 20% from every super-soft Rainbow hoodie purchase to Neuroblastoma UK, to help fund vital research into neuroblastoma, a rare and life-threatening childhood cancer.
London Marathon runner inspired by eight month old cancer patient
Gabriella is running the TCS London Marathon 2023 to raise money for Neuroblastoma UK, after a friend’s son was diagnosed with neuroblastoma last March.
Gabriella first completed the 26.2 mile course in 2019. This year, she is raising money for Neuroblastoma UK after her friend’s eight month old son was diagnosed with high-risk neuroblastoma. She has raised over £5,000 to help fund vital research into this rare and aggressive childhood cancer.
Neuroblastoma UK is delighted to join the growing group of charities from across the UK that have come together for the first Teenage and Young Adult Cancer Awareness Month this April.
Throughout April, our charities will be sharing young people’s experiences of cancer, raising awareness of the unique needs of this age group, showing how we support young people and work to improve their experience through specialised services and research, and highlighting where change is urgently needed.
Cara's memory inspires Banks Group employees to raise £5,000 for Neuroblastoma UK
Employees at North East property and renewable energy firm The Banks Group have smashed their 2022 fundraising target for Neuroblastoma UK. Thank you so much to everyone involved.
The team chose Neuroblastoma UK as their charity of the year in honour of Cara McKay, who sadly passed away in 2020 when she was just three years old.
Recognising researchers this International Women's Day
International Women's Day (8th March) is a global day celebrating the social, economic, cultural, and political achievements of women.
We celebrate the female scientists who work tirelessly to fight childhood cancer - we asked three of our funded researchers about what motivates them in their work to improve treatment for neuroblastoma.
Join #OneCancerVoice in demanding action for cancer patients
England is facing a cancer emergency with missed cancer waiting times, a growing cancer backlog and worsening cancer patient experience. We are lagging behind comparative countries on cancer survival.
That’s why Neuroblastoma UK is speaking up with over 60 cancer charities as #OneCancerVoice. We’re collectively supporting millions of people living with cancer. And we want an ambitious, fully funded, long term strategy on cancer.
Sign the petition today.
Why I took part in RideLondon
Steve Wilkinson completed Ride London in 2022, a 100 mile cycling challenge, and raised over £1,000 for Neuroblastoma UK. He tells us why he got involved and shares some words of encouragement!
Research Grants - a 2022 update
This year we reviewed the current results of the research initially funded by Neuroblastoma UK from 2010 to 2017. Our Symposiums over the last ten years have brought together researchers to share their work and highlight topics, examples are: new treatments, advances in differentiation therapy, genetic landscape of neuroblastoma , the role of MYC gene and micro RNA signatures.
Dr Jinhui Gao, a Research Fellow will be looking into, ‘Investigating the role of Enhancer of Zeste homolog 2 (EZH2) and Natural Killer cells in Neuroblastoma’.
Intensive chemotherapy used in the treatment for high-risk neuroblastoma does not cure all children and has significant side effects and long-term toxicity, so it is imperative that we continue to look for new treatments. One area is to improve the efficacy of immunotherapy. Anti-GD2 immunotherapy is now a mainstay in the therapy of neuroblastoma. Natural killer cells play a major role in the effectiveness of anti-GD2 immunotherapy and EZH2 alters the action of natural killer cells. This pilot study will investigate the benefit of combining EZH2 inhibitors and anti-GD2 immunotherapy.